Novartis Kisqali Shows Exceptional Long-Term Efficacy with 25% of Metastatic Breast Cancer Patients Remaining Progression-Free Beyond Four Years
核心洞察
A pooled analysis of MONALEESA trials revealed that one in four patients with HR+/HER2- metastatic breast cancer (搜索) remained progression-free for four or more years when treated with Kisqali plus endocrine therapy.
Patients achieved a median progression-free survival of 6.8 years, with long-term response observed regardless of menopausal status and even in patients with unfavorable prognostic factors.
Biomarker analysis identified key characteristics associated with long-term response, including lower circulating tumor DNA levels and fewer genetic alterations in CCND1 (搜索) and TP53 (搜索).
Novartis announced groundbreaking results showing that 25% of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (搜索) remained progression-free for four or more years following treatment with Kisqali (ribociclib) plus endocrine therapy. The findings, presented at the 2025 San Antonio Breast Cancer Symposium on December 11, 2025, represent a pooled, post-hoc exploratory analysis of first-line patients from the MONALEESA trials.
Remarkable Long-Term Survival Outcomes
The analysis demonstrated exceptional durability of treatment response, with patients achieving a median progression-free survival of 6.8 years. Notably, the median overall survival was not estimable, indicating that a substantial proportion of patients had not experienced disease progression or death at the time of analysis. The long-term progression-free survival benefit was observed consistently across different patient subgroups, regardless of menopausal status.
"The latest MONALEESA analysis shows that 1 in 4 patients with metastatic disease remained progression-free for four years or more," said Dr. Pedram Razavi, Breast Medical Oncologist and Director of Translational Oncology Partnership Program at Memorial Sloan Kettering Cancer Center, who authored and presented the analysis. "Our biomarker analyses demonstrate clinical and genomic factors potentially associated with these outstanding responses, highlighting the importance of precision medicine in identifying which patients may derive the greatest benefit from CDK4/6 (搜索) inhibitors."
Biomarker Analysis Reveals Predictive Factors
The comprehensive analysis identified distinct characteristics associated with long-term response to Kisqali treatment. Among the 153 long-term responders compared to 349 non-long-term responders, several key differences emerged:
Clinical Characteristics:
- Long-term responders had fewer high-burden cases, with 30% having ≥3 metastatic sites compared to 43% in non-responders
- Liver involvement was less frequent among long-term responders (16% vs 26%)
- Bone-only disease was slightly more common in long-term responders (24% vs 20%)
Molecular Biomarkers:
- Mean circulating tumor DNA (ctDNA) fraction was significantly lower in long-term responders (0.05 vs 0.13)
- CCND1 alterations were less frequent among long-term responders (2% vs 10%)
- TP53 alterations occurred in only 3% of long-term responders compared to 12% of non-responders
- Luminal A subtype was more prevalent among long-term responders (38% vs 25%)
NATALEE Trial Reinforces Early Breast Cancer Benefits
Complementing the metastatic breast cancer (搜索) data, Novartis presented five-year sub-analysis results from the NATALEE trial, demonstrating sustained benefit in early breast cancer (搜索) treatment. The analysis showed that Kisqali plus a nonsteroidal aromatase inhibitor (NSAI) continued to improve distant disease-free survival compared to NSAI alone across key subgroups with both node-positive and node-negative disease.
This reinforces Kisqali plus NSAI as a treatment option for reducing recurrence risk in the broadest population of HR+/HER2- early breast cancer (搜索) patients.
Clinical Significance and Treatment Positioning
Kisqali has established itself as the only CDK4/6 (搜索) inhibitor to demonstrate statistically significant overall survival across all three Phase III MONALEESA trials. The drug has achieved regulatory approval in more than 100 countries worldwide and holds unique distinctions in clinical guidelines.
In the United States, Kisqali is the only CDK4/6 (搜索) inhibitor recommended by NCCN Guidelines as Category 1 preferred for first-line treatment of HR+/HER2- metastatic breast cancer (搜索) when combined with an aromatase inhibitor. For early breast cancer (搜索), it represents the only CDK4/6 inhibitor with Category 1 preferred recommendation for both node-positive disease and high-risk node-negative disease.
The drug has also achieved the highest score (A) on the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) for early breast cancer (搜索) and maintains the highest rating among CDK4/6 (搜索) inhibitors for advanced breast cancer treatment.
Mechanism and Development
Kisqali functions as a selective cyclin-dependent kinase inhibitor, targeting CDK4/6 (搜索) proteins that, when over-activated, enable rapid cancer cell growth and division. The precision targeting of these pathways plays a crucial role in tumor control.
The drug was developed by Novartis under a research collaboration with Astex Pharmaceuticals (搜索) and represents part of Novartis's comprehensive breast cancer portfolio spanning over 30 years of scientific advancement in the field.
"Kisqali continues to deliver on its promise of potentially offering more time for people living with advanced breast cancer," said Mark Rutstein, Global Head of Oncology Development at Novartis. "The results from the long-term analysis provide continued confidence in the clinical benefit of Kisqali for metastatic breast cancer (搜索) patients."